Skip to content

Clinical trials

Phase 1/2 trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Phase: Phase 1/2 Country / region: China Clear all

2,694 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20011
20023
20032
20043
20051
20061
20077
200811
200923
201019
201130
201231
201329
201448
201585
2016125
2017100
201890
2019127
2020159
2021225
2022249
2023299
2024292
2025397
2026315

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting888
Unknown status769
Completed466
Not yet recruiting216
Active, not recruiting168
Terminated113
Withdrawn35
Enrolling by invitation22
Suspended17

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Chinese PLA General Hospital67
Fuda Cancer Hospital, Guangzhou64
Shenzhen Geno-Immune Medical Institute48
Sun Yat-sen University48
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.42
Peking Union Medical College Hospital38
Akeso37
Jiangsu HengRui Medicine Co., Ltd.35
Fudan University31
Suzhou Zelgen Biopharmaceuticals Co.,Ltd29

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Non-Small-Cell Lung145
Recurrence96
Breast Neoplasms89
Colorectal Neoplasms79
Neoplasms79
Carcinoma, Hepatocellular75
Stomach Neoplasms68
Pancreatic Neoplasms66
Leukemia, Myeloid, Acute63
Multiple Myeloma63

Trials

Showing 51 to 75 of 2,694. Each trial links to its page on Pharma Observatory.

2,594 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.